Pfizer Inc. / Biohaven Pharmaceutical Holding Company Ltd.
2022 · Acquisition/Merger · $11.6B · Complete
Announcement Sentiment
90
Strongly positive
Outcome Score
69
Largely worked — most objectives met.
Pfizer acquired Biohaven Pharmaceuticals for approximately $11.6 billion ($148.50 per share in cash), gaining Nurtec ODT (rimegepant), a dual-action CGRP receptor antagonist approved for both acute treatment and prevention of migraine. Prior to closing, Biohaven spun off its non-CGRP pipeline into a new public entity.